Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

J&J Reports Q4 2024 Results; Annual Darzalex® Sales Total USD11.7B

Jan 22, 2025

On 22 January 2025, Johnson & Johnson (J&J) reported its results for Q4 2024, which saw sales growth of 5.3% to $22.5B.

On the same day, Genmab announced that worldwide annual net sales of Darzalex® (daratumumab) for 2024, as reported by J&J, totalled USD11.7 billion.  US sales accounted for more than half of this total, reaching USD6.6 billion.  Genmab receives royalties on the worldwide net sales of Darzalex® (IV and SC), under its exclusive worldwide licence to Janssen to develop, manufacture and commercialise daratumumab.

J&J reports that it achieved several significant regulatory milestones in Q4 2024 across the EU and US.  This includes the European approval for several new indications of J&J biologics, such as Darzalex® SC based quadruplet regimen for multiple myeloma (October 2024), and Rybrevant® (amivantamab) in combination with Lazcluze® (lazertinib) for non-small cell lung cancer (December 2024).  J&J also submitted an application in the EU for approval of Darzalex® SC for high-risk smouldering multiple myeloma (November 2024).

In the US, J&J submitted an application for approval of a new indication of Darzalex Faspro® (daratumumab and hyaluronidase-hj) for high-risk smouldering multiple myeloma (November 2024), and received Breakthrough Therapy designation (BTD) for nipocalimab for the treatment of adults living with moderate-to-severe Sjögren’s disease (November 2024).  J&J also sought FDA approval for a subcutaneous induction regimen of Tremfya® (guselkumab) for ulcerative colitis (November 2024).